Skip to search formSkip to main contentSkip to account menu

Citatuzumab Bogatox

Known as: Anti-EpCAM Antibody Fragment-Bouganin Fusion Protein, VB6-845 
A fusion protein immunotoxin consisting of a humanized, single-chain monoclonal antibody Fab fragment specific for the epithelial cell adhesion… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
The Preclinical and Clinical Evaluation of VB 6-845 : An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors
One of the challenges in cancer therapy is to eradicate tumor cells while minimizing the toxic side effects to normal tissue that… 
2011
2011
Intracellular trafficking of VB 6-845 , an immunocytotoxin containing a de-immunized variant of bouganin
Recombinant immunocytotoxins consist of an antibody-binding domain fused with a cytotoxin. The specificity of the antibody… 
2011
2011
A preclinical profile of VB 6-845 : a recombinant immunotoxin for targeting ovarian cancer
Ovarian cancer is the fourth most common cause of cancer mortality in women. Most patients present with advanced disease due to… 
2010
2010
Complete regression of ovarian cancer xenografts following treatment with the recombinant immunocytotoxic protein , VB 6-845
VB6-845 is a recombinant fusion construct consisting of a tumor-targeting Fab linked to de-immunized Bouganin, a type 1 ribosome… 
2008
2008
A phase I study of VB6-845, an anti-EpCAM fusion protein targeting advanced solid tumours of epithelial origin: preliminary results
14663 Background: VB6–845 is a recombinant fusion protein comprised of a humanized Fab anti-EpCAM antibody linked to a de… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)